Background: The FDA-approved drugs for female sexual interest, desire and/or arousal
disorder (FSIAD), and hypoactive sexual desire disorder (HSDD); however, these drugs have low
tolerability for patients because of their multiple side effects and do not show actual therapeutic efficacy.
Hypoactive Sexual Desire affects approximately 750.000.000 to 1.400.000.000 people
Methods: In this paper, we analyze therapeutic candidates in clinical practice as well as the methodologies
of clinicaltrials of possible therapeutic targets of different systems related to the disorder.
Results: Therefore, clinical trials of new drugs (benzodiazepines, amphetamines, testosterone, sildenafil,
or new compound) to evaluate their efficacy in treating this disorder are necessary.